102.57
0.12%
-0.12
Novartis AG ADR stock is currently priced at $102.57, with a 24-hour trading volume of 777.53K.
It has seen a -0.12% decreased in the last 24 hours and a +10.20% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $102.5 pivot point. If it approaches the $102.9 resistance level, significant changes may occur.
Previous Close:
$102.69
Open:
$102.87
24h Volume:
777.53K
Market Cap:
$209.28B
Revenue:
$49.92B
Net Income/Loss:
$15.25B
P/E Ratio:
27.57
EPS:
3.72
Net Cash Flow:
$10.25B
1W Performance:
+0.46%
1M Performance:
+10.20%
6M Performance:
+8.07%
1Y Performance:
+1.33%
Novartis AG ADR Stock (NVS) Company Profile
Name
Novartis AG ADR
Sector
Industry
Phone
41 61 324 1111
Address
Lichtstrasse 35, Basel
Novartis AG ADR Stock (NVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-23-24 | Initiated | BMO Capital Markets | Market Perform |
Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
Jan-16-24 | Resumed | UBS | Buy |
Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
Sep-25-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Apr-26-23 | Upgrade | Deutsche Bank | Hold → Buy |
Mar-27-23 | Upgrade | Deutsche Bank | Sell → Hold |
Jan-26-23 | Downgrade | Citigroup | Buy → Neutral |
Dec-05-22 | Upgrade | Stifel | Hold → Buy |
Sep-15-22 | Downgrade | Credit Suisse | Neutral → Underperform |
Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
May-09-22 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Jan-10-22 | Resumed | Citigroup | Buy |
Dec-14-21 | Downgrade | Redburn | Buy → Neutral |
Dec-06-21 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Dec-03-21 | Downgrade | Bryan Garnier | Buy → Neutral |
Sep-20-21 | Downgrade | Deutsche Bank | Hold → Sell |
Mar-22-21 | Initiated | Bernstein | Mkt Perform |
Mar-10-21 | Downgrade | Argus | Buy → Hold |
Feb-01-21 | Downgrade | Cowen | Outperform → Market Perform |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Buy |
Sep-10-20 | Upgrade | UBS | Neutral → Buy |
Sep-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-15-20 | Upgrade | Citigroup | Neutral → Buy |
Mar-10-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-25-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-25-19 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-19 | Upgrade | Liberum | Hold → Buy |
Apr-10-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-02-19 | Downgrade | JP Morgan | Neutral → Underweight |
Dec-11-18 | Resumed | Jefferies | Buy |
Oct-09-18 | Initiated | Guggenheim | Neutral |
Sep-10-18 | Upgrade | BofA/Merrill | Underperform → Buy |
May-29-18 | Downgrade | HSBC Securities | Buy → Hold |
May-25-18 | Upgrade | Credit Suisse | Underperform → Neutral |
Jan-25-18 | Reiterated | Leerink Partners | Outperform |
Dec-06-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
Jul-26-17 | Upgrade | Morgan Stanley | Underweight → Overweight |
Jul-05-17 | Downgrade | Credit Suisse | Neutral → Underperform |
Mar-09-17 | Initiated | Liberum | Buy |
View All
Novartis AG ADR Stock (NVS) Latest News
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA - Yahoo Movies UK
Yahoo Movies UK
Pfizer: Best Trading Momentum Since 2021 And 6% Yield
Seeking Alpha
3 Magnificent Stocks That Are Passive Income Machines
The Motley Fool
Novartis' (NVS) Shareholders Approve Sandoz Separation - Yahoo Movies Canada
Yahoo Movies Canada
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs - Yahoo News Australia
Yahoo News Australia
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
Benzinga
Novartis AG ADR Stock (NVS) Financials Data
Novartis AG ADR (NVS) Revenue 2024
NVS reported a revenue (TTM) of $49.92 billion for the quarter ending March 31, 2024, a +8.81% rise year-over-year.
Novartis AG ADR (NVS) Net Income 2024
NVS net income (TTM) was $15.24 billion for the quarter ending March 31, 2024, a +116.98% increase year-over-year.
Novartis AG ADR (NVS) Cash Flow 2024
NVS recorded a free cash flow (TTM) of $10.25 billion for the quarter ending March 31, 2024, a -25.62% decrease year-over-year.
Novartis AG ADR (NVS) Earnings per Share 2024
NVS earnings per share (TTM) was $7.33 for the quarter ending March 31, 2024, a +125.54% growth year-over-year.
About Novartis AG ADR
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; QIAGEN N.V.; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Cap:
|
Volume (24h):